Maravai LifeSciences/$MRVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Maravai LifeSciences
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Ticker
$MRVI
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
580
ISIN
US56600D1072
Website
MRVI Metrics
BasicAdvanced
$361M
-
-$1.16
0.19
-
Price and volume
Market cap
$361M
Beta
0.19
52-week high
$10.03
52-week low
$1.67
Average daily volume
1.8M
Financial strength
Current ratio
5.958
Quick ratio
4.964
Long term debt to equity
68.651
Total debt to equity
71.848
Interest coverage (TTM)
-2.05%
Profitability
EBITDA (TTM)
-39.886
Gross margin (TTM)
37.29%
Net profit margin (TTM)
-67.28%
Operating margin (TTM)
-36.94%
Effective tax rate (TTM)
0.67%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-4.64%
Return on equity (TTM)
-44.32%
Valuation
Price to revenue (TTM)
1.46
Price to book
1.2
Price to tangible book (TTM)
-6.14
Price to free cash flow (TTM)
-14.6
Free cash flow yield (TTM)
-6.85%
Free cash flow per share (TTM)
-17.19%
Growth
Revenue change (TTM)
-11.76%
Earnings per share change (TTM)
16.57%
3-year revenue growth (CAGR)
-35.36%
3-year earnings per share growth (CAGR)
-12.14%
What the Analysts think about MRVI
Analyst ratings (Buy, Hold, Sell) for Maravai LifeSciences stock.
Bulls say / Bears say
Maravai LifeSciences has expanded its capabilities by acquiring the DNA and RNA business of Officinae Bio, enhancing its mRNA design and manufacturing services. (nasdaq.com)
The company has entered into a partnership with VWR to distribute TriLink BioTechnologies' products across Europe, the Middle East, and Africa, potentially increasing its market reach. (nasdaq.com)
Maravai has appointed R. Andrew Eckert as independent Chairman of the Board, bringing experienced leadership to guide the company's strategic direction. (nasdaq.com)
The company reported a net loss of $259.6 million for the full year 2024, a significant increase from the previous year's loss of $138.4 million. (nasdaq.com)
Fourth quarter revenue decreased by 23.7% year-over-year, indicating a concerning decline in business performance. (nasdaq.com)
A goodwill impairment of $166.2 million was recorded for the Nucleic Acid Production segment, suggesting potential overvaluation of acquired assets. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
MRVI Financial Performance
Revenues and expenses
MRVI Earnings Performance
Company profitability
MRVI News
AllArticlesVideos

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer
GlobeNewsWire·1 week ago

Maravai ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·1 week ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Maravai LifeSciences stock?
Maravai LifeSciences (MRVI) has a market cap of $361M as of July 02, 2025.
What is the P/E ratio for Maravai LifeSciences stock?
The price to earnings (P/E) ratio for Maravai LifeSciences (MRVI) stock is 0 as of July 02, 2025.
Does Maravai LifeSciences stock pay dividends?
No, Maravai LifeSciences (MRVI) stock does not pay dividends to its shareholders as of July 02, 2025.
When is the next Maravai LifeSciences dividend payment date?
Maravai LifeSciences (MRVI) stock does not pay dividends to its shareholders.
What is the beta indicator for Maravai LifeSciences?
Maravai LifeSciences (MRVI) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.